“…There is an array of data demonstrating chemerin may be intertwined with CKM driving pathways. In humans, SIRT1 concentrations in serum/plasma are lower in patients with aortic aneurysm [34], stroke [35] and prior history of myocardial infarction [36], but also type 2 diabetic nephropathy [37]. Circulating chemerin is associated with dysfunctional adiposity measures (obesity, lipid alterations) and blood pressure [38], as well as being an independent marker of arterial stiffness, even after adjustment for confounders [39].…”